Rinna Tei1, Koji Iijima2, Koji Matsumoto2, Takao Kobayashi2, Jyoti Lama3, Elizabeth A Jacobsen4, Hirohito Kita5. 1. Division of Allergy, Asthma and Clinical Immunology and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi, Japan. 2. Division of Allergy, Asthma and Clinical Immunology and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz. 3. Immunology Program, Mayo Graduate School of Biomedical Sciences, Rochester, Minn and Scottsdale, Ariz. 4. Division of Allergy, Asthma and Clinical Immunology and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Immunology, Mayo Clinic Rochester, Rochester, Minn, and Mayo Clinic Arizona, Scottsdale, Ariz. 5. Division of Allergy, Asthma and Clinical Immunology and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Immunology, Mayo Clinic Rochester, Rochester, Minn, and Mayo Clinic Arizona, Scottsdale, Ariz. Electronic address: kita.hirohito@mayo.edu.
Abstract
BACKGROUND: Group 2 innate lymphoid cells (ILC2s) are involved in type 2 immune responses in mucosal organs and are associated with various allergic diseases in humans. Studies are needed to understand the molecules and pathways that control ILC2s. OBJECTIVE: The aims of this study were to develop a mouse model that limits the innate type 2 immune response in the lung and to investigate the immunologic mechanisms involved in regulation of lung ILC2s. METHODS: Naive BALB/c mice were administered various Toll-like receptor agonists and exposed intranasally to the fungal allergen Alternaria alternata. The mechanisms were investigated using gene knockout mice as well as cultures of lung cells and isolated lung ILC2s. RESULTS: Polyinosinic-polycytidylic acid, or poly (I:C), effectively inhibited innate type 2 response to A alternata. Poly (I:C) promoted production of IFNα, -β, and -γ, and its inhibitory effects were dependent on the IFN-α/β receptor pathway. IFN-β was 100 times more potent than IFN-α at inhibiting type 2 cytokine production by lung ILC2s. Signal transducer and activator of transcription 5 (STAT5)-activating cytokines, including IL-2, IL-7, and thymic stromal lymphopoietin, but not IL-33, promoted survival and proliferation of lung ILC2s in vitro, while IFN-β blocked these effects. Expression of the transcription factor GATA3, which is critical for differentiation and maintenance of ILC2s, was inhibited by IFN-β. CONCLUSIONS: IFN-β blocks the effects of STAT5-activating cytokines on lung ILC2s and inhibits their survival and effector functions. Administration of IFN-β may provide a new strategy to treat diseases involving ILC2s.
BACKGROUND: Group 2 innate lymphoid cells (ILC2s) are involved in type 2 immune responses in mucosal organs and are associated with various allergic diseases in humans. Studies are needed to understand the molecules and pathways that control ILC2s. OBJECTIVE: The aims of this study were to develop a mouse model that limits the innate type 2 immune response in the lung and to investigate the immunologic mechanisms involved in regulation of lung ILC2s. METHODS: Naive BALB/c mice were administered various Toll-like receptor agonists and exposed intranasally to the fungal allergen Alternaria alternata. The mechanisms were investigated using gene knockout mice as well as cultures of lung cells and isolated lung ILC2s. RESULTS: Polyinosinic-polycytidylic acid, or poly (I:C), effectively inhibited innate type 2 response to A alternata. Poly (I:C) promoted production of IFNα, -β, and -γ, and its inhibitory effects were dependent on the IFN-α/β receptor pathway. IFN-β was 100 times more potent than IFN-α at inhibiting type 2 cytokine production by lung ILC2s. Signal transducer and activator of transcription 5 (STAT5)-activating cytokines, including IL-2, IL-7, and thymic stromal lymphopoietin, but not IL-33, promoted survival and proliferation of lung ILC2s in vitro, while IFN-β blocked these effects. Expression of the transcription factor GATA3, which is critical for differentiation and maintenance of ILC2s, was inhibited by IFN-β. CONCLUSIONS: IFN-β blocks the effects of STAT5-activating cytokines on lung ILC2s and inhibits their survival and effector functions. Administration of IFN-β may provide a new strategy to treat diseases involving ILC2s.
Authors: Daniel F Gudbjartsson; Unnur S Bjornsdottir; Eva Halapi; Anna Helgadottir; Patrick Sulem; Gudrun M Jonsdottir; Gudmar Thorleifsson; Hafdis Helgadottir; Valgerdur Steinthorsdottir; Hreinn Stefansson; Carolyn Williams; Jennie Hui; John Beilby; Nicole M Warrington; Alan James; Lyle J Palmer; Gerard H Koppelman; Andrea Heinzmann; Marcus Krueger; H Marike Boezen; Amanda Wheatley; Janine Altmuller; Hyoung Doo Shin; Soo-Taek Uh; Hyun Sub Cheong; Brynja Jonsdottir; David Gislason; Choon-Sik Park; Linda M Rasmussen; Celeste Porsbjerg; Jakob W Hansen; Vibeke Backer; Thomas Werge; Christer Janson; Ulla-Britt Jönsson; Maggie C Y Ng; Juliana Chan; Wing Yee So; Ronald Ma; Svati H Shah; Christopher B Granger; Arshed A Quyyumi; Allan I Levey; Viola Vaccarino; Muredach P Reilly; Daniel J Rader; Michael J A Williams; Andre M van Rij; Gregory T Jones; Elisabetta Trabetti; Giovanni Malerba; Pier Franco Pignatti; Attilio Boner; Lydia Pescollderungg; Domenico Girelli; Oliviero Olivieri; Nicola Martinelli; Bjorn R Ludviksson; Dora Ludviksdottir; Gudmundur I Eyjolfsson; David Arnar; Gudmundur Thorgeirsson; Klaus Deichmann; Philip J Thompson; Matthias Wjst; Ian P Hall; Dirkje S Postma; Thorarinn Gislason; Jeffrey Gulcher; Augustine Kong; Ingileif Jonsdottir; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2009-02-08 Impact factor: 38.330
Authors: Peter A B Wark; Sebastian L Johnston; Fabio Bucchieri; Robert Powell; Sarah Puddicombe; Vasile Laza-Stanca; Stephen T Holgate; Donna E Davies Journal: J Exp Med Date: 2005-03-21 Impact factor: 14.307
Authors: Alejandro V Villarino; Giuseppe Sciumè; Fred P Davis; Shigeru Iwata; Beatrice Zitti; Gertraud W Robinson; Lothar Hennighausen; Yuka Kanno; John J O'Shea Journal: J Exp Med Date: 2017-09-15 Impact factor: 14.307